Asher M. Rubin

• Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of patients with retinal and refractive eye disorders, in an all-stock acquisition of Opus Genetics, Inc., a clinical-stage gene therapy company for inherited retinal diseases.
• Radiant Biotherapeutics, a preclinical biotechnology company developing an antibody platform to deliver transformative therapies for patients facing life-changing disease, in its US$35 million Series A financing.
• HealthCare Royalty in the negotiation of a US$250 million non-dilutive note purchase agreement with OPKO Health, Inc. (NASDAQ: OPK) secured by OPKO’s profit share payments from Pfizer Inc. received pursuant to its license agreement relating to NGENLA™, a once-weekly treatment marketed to treat pediatric growth hormone deficiency.
• OMERS Life Sciences in the $650 million strategic financing of Verona Pharm plc (NASDAQ: VRNA) together with funds managed by Oaktree Capital Management, L.P., consisting of up to US$400 million in term loans and up to US$250 million in funding from the sale of a redeemable capped interest in future ensifentrine-related revenue.
• OMERS Life Sciences in its acquisition of a capped, tiered, declining royalty on direct annual net sales of ORLADEYO® (berotralstat) from BioCryst Pharmaceuticals, Inc. for US$150 million.
• OMERS Life Sciences in the negotiation of a definitive credit facility agreement for BridgeBio Pharma, Inc. with a syndicate of lenders for up to US$750 million in financing.
• Sagard Healthcare in purchasing a 1% royalty in net sales of Tyvaso DPI® (treprostinil) inhalation powder from MannKind Corporation (Nasdaq: MNKD), in exchange for up to US$200 million, including the purchase price of US$150 million and an additional potential milestone payment of up to US$50 million.
• Praxis Precision Medicines, Inc. (NASDAQ: PRAX) in an exclusive collaboration and license agreement with Tenacia Biotechnology (Shanghai) Company, Ltd. for the development and commercialization of ulixacaltamide for the treatment of essential tremor in Greater China.
• Shinobi Therapeutics, a biotechnology company developing a new class of immune-evasive iPS-T cell therapies, in its US$51 million Series A financing.
• Novo Nordisk Inc. (NYSE: NVO) in its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN², a translational drug discovery accelerator that aims to nurture early research from academic institutions into novel therapeutics. The focus of the collaboration is to accelerate the translation of academic ideas to therapeutic product candidates in the cardiometabolic space.
• The underwriters in the upsized US$198.7 million initial public offering by Tyra Biosciences, Inc., a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
• Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, in its US$76 million Series A financing.
• Biolojic Design in the formation of Aulos; Lilly collaboration and Nektar collaboration.
• Acrivon in collaboration with Lilly.
• SciNeuro in its license agreement with Lilly.
• Delfi Diagnostics in its US$101M series A offering.
• AavantiBio in its US$107M series A offering. 
• Pyxis Oncology in its license with LegoChem and Pfizer.
• Fairmont Funds in connection with several strategic transactions for its portfolio companies. 
• Zenas Biopharma in its license with Viridian. 
• Merck in connection with its license with IDRI.
• Lesaffre in its strategic collaboration and investment with Recombia.
• Spectrum Pharmaceuticals on the sale of its portfolio of seven FDA-approved hematology and oncology products to Acrotech Biopharma L.L.C.
• OPKO, Inc. on its development and commercial licensing agreement with Pfizer, Inc.
• OPKO on its licensing agreement with Japan Tobacco for the international development and marketing of Rayaldee.
• Intellia Therapeutics in its research collaboration and license agreement with GEMoaB to discover and develop allogeneic cellular immunotherapies for cancers and inflammatory diseases.
• Daiichi Sankyo on its joint collaboration with AstraZeneca to develop and commercialize Daiichi Sankyo's DS-1062, a potential new medicine to treat multiple tumor types.
• Kiadis Pharma in connection with the acquisition of CytoSen Therapeutics, Inc.
• Galera Therapeutics on the development of drugs targeting oxygen metabolic pathways in connection with an US$80m royalty financing with Clarus (later acquired by Blackstone).
• NextCure in connection with its formation, US$67m Series A financing, IPO, and follow on offering.
• NextCure on its multi-year collaboration with Eli Lilly focused on the discovery and development of immuno-oncology therapies.
• NextCure in its license and sponsored research agreements with Yale University.
• Exact Sciences Corp. on its collaboration agreement with Pfizer to co-promote Cologuard, the first and only FDA-approved non-invasive stool DNA screening test for colorectal cancer.
• TESARO on its acquisition by GlaxoSmithKline (GSK).
• TESARO in its US$101m Series B financing, its IPO, all of its follow-on equity financings, and US$165m notes financing.
• TESARO in connection with its acquisition of rights to its niraparib PARP inhibitor, ALK inhibitor, and checkpoint inhibitor programs.
• TESARO in its collaboration and license agreement with Janssen Biotech involving niraparib for the treatment of prostate cancer.
• TESARO in its exclusive licensing agreement with Takeda for the commercialization and clinical development of niraparib in Japan.
• Amplimmune, Inc. in connection with its sale for up to US$500m to AstraZeneca.
• New Enterprise Associates and Apple Tree Partners in several venture capital financings of companies at various stages of development.
• The University of Pennsylvania in connection with its exclusive license and collaboration of CAR-T technologies to Novartis.
• Immune Design Corp., in connection with its exclusive licenses to a pharmaceutical company for food allergies and HSV.
• Braeburn Pharmaceuticals on its US$110m mezzanine round of financing led by Wellington Management Company.
• Incyte Corp. in its license and collaboration agreement with MacroGenics relating to an anti-PD-1 antibody.
• Vivus on its acquisition of Pancreaze from Janssen Pharmaceuticals and its acquisition of Willow BioPharma.
• Fibrocell Science, Inc. on their acquisition by Castle Creek Pharmaceutical, Inc. with a total transaction value of approximately US$63.3m.

*Some of the above matters were handled prior to joining Sidley.

• Member, Maryland State Bar Association
• Board of Directors, Shriver Hall Concert Series
• Board of Directors, Sinai Hospital (past member)
• Board of Directors, Lifebridge Innovation (past member)